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RESEARCH
Benchmarking network propagation methods for
disease gene identification
Sergio Picart-Armada1,2*, Steven J. Barrett4, David R. Wille´4, Alexandre Perera-Lluna1,2, Alex
Gutteridge3 and Benoit H. Dessailly5
Abstract
Background: In-silico identification of potential disease genes has become an essential aspect of drug target
discovery. Recent studies suggest that one powerful way to identify successful targets is through the use of
genetic and genomic information. Given a known disease gene, leveraging intermolecular connections via
networks and pathways seems a natural way to identify other genes and proteins that are involved in similar
biological processes, and that can therefore be analysed as additional targets.
Results: Here, we systematically tested the ability of 12 varied network-based algorithms to identify target
genes and cross-validated these using gene-disease data from Open Targets on 22 common diseases. We
considered two biological networks, six performance metrics and compared two types of input gene-disease
association scores. We also compared several cross-validation schemes and showed that different choices had a
remarkable impact on the performance estimates. When seeding biological networks with known drug targets,
we found that machine learning and diffusion-based methods are able to find novel targets, showing around 2-4
true hits in the top 20 suggestions. Seeding the networks with genes associated to disease by genetics resulted
in poorer performance, below 1 true hit on average. We also observed that the use of a larger network,
although noisier, improved overall performance.
Conclusions: We conclude that machine learning and diffusion-based prioritisers are suited for drug discovery
in practice and improve over simpler neighbour-voting methods. We also demonstrate the large effect of several
factors on prediction performance, especially the validation strategy, input biological network, and definition of
seed disease genes.
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cross validation; protein complexes
*Correspondence:
sergi.picart@upc.edu
1B2SLab, Departament
d’Enginyeria de Sistemes,
Automa`tica i Informa`tica
Industrial, Universitat Polite`cnica
de Catalunya, CIBER-BBN,
08028, Barcelona, Spain
Full list of author information is
available at the end of the article
†Equal contributor
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/439620doi: bioRxiv preprint first posted online Oct. 11, 2018; 
Picart-Armada et al. Page 2 of 28
1 1
2 2
3 3
4 4
5 5
6 6
7 7
8 8
9 9
10 10
11 11
12 12
13 13
14 14
15 15
16 16
17 17
18 18
19 19
20 20
21 21
22 22
23 23
24 24
25 25
26 26
27 27
28 28
29 29
30 30
31 31
32 32
33 33
Background
The pharmaceutical industry faces considerable challenges in the efficiency of com-
mercial drug research and development [1] and in particular in improving its ability
to identify future successful drug targets.
It has been suggested that using genetic association information is one of the best
ways to identify such drug targets [2]. In recent years, a large number of highly
powered GWAS studies have been published for numerous common traits (see for
example [3] or [4]) and have yielded many candidate genes. Further potential targets
can be identified by adding contextual data to the genetic associations, such as genes
involved in similar biological processes [5, 6]. Biological networks and biological
pathways can be used as a source of contextual data.
Biological networks are widely used in bioinformatics and can be constructed from
multiple data sources, ranging from macromolecular interaction data collected from
the literature [7] to correlation of expression in transcriptomics or proteomics sam-
ples of interest [8]. A large number of interaction network resources have been made
available over the years, many of which are now in the public domain, combining
thousands of interactions in a single location [9, 10]. They are based on three dif-
ferent fundamental types of data: (1) data-driven networks such as those built by
WGCNA [8] for co-expression; (2) interactions extracted from the literature using
a human curation process as exemplified by IntAct [11] or BioGRID [12]; and (3)
interactions extracted from the literature using text mining approaches [13].
On the other hand, a plethora of network analysis algorithms are available for
extracting useful information from such large biological networks in a variety of
contexts. Algorithms range in complexity from simple first-neighbour approaches,
where the direct neighbours of a gene of interest are assumed to be implicated in
similar processes [14], to machine learning (ML) algorithms designed to learn from
the features of the network to make more useful biological predictions (e.g. [15]).
One broad family of network analysis algorithms are the so-called Network Prop-
agation approaches [16], used in contexts such as protein function prediction [17],
disease gene identification [16] and cancer gene mutation identification [18]. In this
paper, we perform a systematic review of the usefulness of network analysis methods
for the purpose of identification of disease genes susceptible of being drug targets.
Claims that such methods are helpful in that context have been made on numerous
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occasions but a comprehensive validation study is lacking. One major challenge in
doing such a study is that it is not straightforward to define a list of known disease
genes to be used for this purpose.
To address this, the Open Targets collaboration has been setup between phar-
maceutical companies and public institutions to collect information on known drug
targets and to help identify new ones [19]. A dedicated internet platform provides
a free-to-use accessible resource summarising known data on gene-disease relation-
ships from a number of data sources (e.g. known released drugs, genetic associations
from GWAS, etc) [19].
The purpose of this work is to quantify the performance of network-based meth-
ods to prioritise novel targets, using various networks and validation schemes, and
aiming at a faithful reflection of a realistic drug development scenario. We select
a number of network approaches that are representative of several classes of algo-
rithms, and test their ability to recover known disease genes by cross-validation.
We benchmark multiple definitions of disease genes, computational methods, bi-
ological networks, validation schemes and performance metrics. We account for all
possible combinations of such factors and derive guidelines for future disease gene
identification studies.
Results
Benchmark framework
Our general approach, summarised in figure 1, consisted in using a biological net-
work and a list of genes with prior disease-association scores as input to a network
propagation approach. We used three cross-validation schemes -two take into ac-
count protein complexes- in which some of the prior disease-association scores are
hidden. The desired output was a new ranking of genes in terms of their association
scores to the disease. Such ranking was compared to the known disease genes in
the validation fold using several performance metrics. Given the amount of design
factors and comparisons, the metrics were analysed through explorative additive
models (see Methods). Alternatively, we provide plots on the raw metrics in the
supplement, stratified by method in figures S10 and S11 or by disease in figures S12
and S13.
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We considered 2 metrics (AUROC and top 20 hits) and 2 input types (known drug
target genes and genetically associated genes), resulting in a total of 4 combinations,
each described through an additive main effect model. Another 4 metrics were
explored and can be found in the supplement (figure S17 and tables S6, S7).
Interactions were explored, but they did not provide any added value for the
extra complexity (see figure S18 from the supplement). The metrics used were the
dependent variables, while the regressors included the prediction method, the CV
scheme, the network and the disease.
Performance using known drug targets as input
Figure 2 describes the additive models for AUROC and top 20 hits, and using known
drug targets as input. Figure 3 contains their predictions for each method, network
and cross validation scheme with 95% confidence intervals, averaged over diseases.
The models are complex and we therefore review each main effect separately.
AUPRC (quasi-binomial model) and top 20 hits (quasi-poisson) behave alike, as
can be observed by their similar ranking of model estimates in Figure 2. For inter-
pretability within real scenarios, only top 20 hits is shown in the main body. The
standard AUROC (quasi-binomial) clearly led to different conclusions and is kept
throughout the results section for comparison. The remaining metrics (AUPRC,
pAUROC 5%, pAUROC 10% and top 100 hits) result in similar method prioritisa-
tions as top 20 hits, see figure S17. Detailed models can be found in the supplement,
indexed by tables S6 and S7.
Comparing cross-validation schemes
Whether protein complexes were properly taken into account when performing the
cross-validation (see Methods) stood out as a key influence on the quality of predic-
tions: there was a dramatic reduction in performance for most methods when using
a complex-aware cross-validation strategy. For instance, method rf applied on the
STRING network dropped from almost 12 correct hits in the top 20 predicted dis-
ease genes when using our classic cross-validation scheme down to fewer than 4.5
when using either of our complex-aware cross-validation schemes. Likewise, table S5
from the supplement ratifies that only the classic cross validation splits complexes.
Our data suggests that the performance drop when choosing the appropriate
validation strategy is comparable to the performance gap of competitive methods
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versus a simple neighbour-voting baseline (see figure 2). This highlights the im-
portance of carefully controlling for this bias when estimating the performance of
network-based disease gene prediction methods. Overall, the classic cross-validation
scheme gave biased estimates in our dataset, whereas our block and representative
cross-validation schemes had similar effects on the prediction performance. Method
ranking was independent of the cross validation choice thanks to the use of an addi-
tive model. And since both the block and representative schemes make theoretical
sense, we chose to focus on results from the block scheme in the rest of this study.
Comparing networks
We found that using STRING as opposite to OmniPath improved overall perfor-
mance of network-based disease gene prediction methods. Our models for top 20
hits quantified this effect as noticeable although less important than that of the
cross validation strategy. For reference, method rf obtains about 3 true hits under
both complex-aware strategies in OmniPath. It has been previously shown that the
positive effect on predictive power of having more interactions and coverage in a
network can outweigh the negative effect of increased number of false positive in-
teractions [20], which is in line with our findings. The authors also report STRING
among the best resources to discover disease genes, which is a finding we reproduce
here.
We focus on the STRING results in the rest of the text.
Comparing methods
Having identified the optimal cross-validation scheme and network for our bench-
mark in the previous sections, we quantitatively compared the performance of the
different methods.
First, network topology alone had a slight predictive power, as method pr (PageR-
ank approach that ignores the input gene scores) showed better performance than
the random baseline under all the metrics. The randomised diffusion randomraw
lied between random and pr in performance. Both facts support the existence of an
inherent network topology-related bias among the positives that benefits diffusion-
based methods.
Second, the basic GBA approach from EGAD had an advantage over the input-
na¨ıve baselines pr, randomraw and random. It also outperformed prioritizing genes
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using other Open Targets data stream scores such as genes associated to disease
from pathways or from the literature (see supplement, table S19).
Most diffusion-based and ML-based methods outperformed EGAD. Results from
top 20 hits suggest using rf for the best performance followed by, in order: raw and
bagsvm, z and svm (main models panel in Figure 6).
To formally test the differences between methods, we carried a Tukey’s multi-
ple comparison test on the model coefficients (Figure 5) as implemented in the R
package multcomp [21]. Although such differences were in most cases statistically
significant, even with such a strong multiplicity adjustment, their actual effect size
or magnitude can be modest in practice, see Figures 3 and 6.
The ranking of methods was similar when using the metrics AUPRC, pAUROC
and top k hits (see supplement, figure S17) and is only intended to be a general
reference, given the impact of the problem definition, cross validation scheme and
the network choice.
With AUROC on the other hand, rf lost its edge whilst most diffusion-based
and ML-based methods appeared technically tied. Despite its theoretical basis, in-
terpretability and widespread use in similar benchmarks, these results support the
assertion that AUROC is a sub-optimal choice in drug discovery practical scenarios.
Figure 4 further shows how the different methods compare with one another. Dis-
tances between each pair of method in terms of their top 100 novel predictions were
represented graphically. From this we observe that the supervised bagged SVM ap-
proach (bagsvm) behaves similarly to the simple diffusion approach (raw), reflecting
the fact that they use the same kernel. We also observe that diffusion approaches do
not necessarily produce similar results (compare for example raw and z). And that
interestingly, methods EGAD (arguably one of the simplest) and COSNet (arguably
one of the most complex) seemed to result in similar predictions. Fully supervised
and semi-supervised approaches largely group in the top right hand quadrant of the
STRING plot away from diffusion methods, possibly showing some shared greater
potential for “learning effect” with the larger network.
Interestingly, when comparing overall performances shown in figure 6 with the
prediction differences from the MDS plot (figure 4), it appears that the better
performing methods may be doing well for different reasons as they do not occur
within the same region of the plot (e.g. rf and raw). MDS plots on the eight possible
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combinations of network, input type and inclusion of seed genes are displayed in
the supplementary figures S15 and S16.
Regarding the STRING network and the block validation scheme, we fitted six
additive models (one per metric) to the known drug target data (see supplement,
table S7) and prioritised the methods (reduced models in figure 6). These reduced
models better described this particular scenario, as they were not forced to fit the
trends in all networks and validation schemes in an additive way. Considering the
top 20 hits, rf and svm were the optimal choices, followed by wsld and knn.
Comparing diseases
We next examine performance by disease. The top 20 hits model in figure 2 shows
that allergy (the figure’s baseline reference), ulcerative colitis and rheumatoid arthri-
tis (group I) are the diseases for which prediction of disease genes was worst, whereas
cardiac arrhythmia, Parkinson’s disease, stroke and multiple sclerosis (group II) are
those for which it was best. As shown in figure 7, group I diseases had fewer known
disease genes and lower modularity compared to group II diseases.
Prediction methods worked better when more known disease genes were available
as input in the network, with two possible underlying reasons being the greater
data availability to train the methods, and the natural bias of top 20 hits towards
datasets with more positives. Likewise, a stronger modularity within disease genes
justifies the guilt-by-association principle and led to better performances. In turn,
the number of genes and the modularity were positively correlated, see supplement,
figure S14.
Performance using genetic associations as input
Using genetically associated genes as input to a prediction approach to find known
drug targets mimicked a realistic scenario where novel genetic associations are
screened as potential targets. However, inferring known drug targets through the
indirect genetic evidence posed problems to prediction strategies, especially those
based on machine learning. Learning is done using one class of genes in order to pre-
dict genes that belong to another class, and the learning space suffers from intrinsic
uncertainties in the genetic associations to disease.
Consequently, we observed a major performance drop on all the prioritisation
methods: using any network and cross-validation scheme, the predicted top 20 hits
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were practically bounded by 1. This was more pronounced on supervised machine
learning-focused strategies, as rf and svm lost their edge on diffusion-based strate-
gies. The fact that the genetic associations of the validation fold were hidden further
hindered the predictions and can be a cause of our pessimistic performance esti-
mates.
Comparing cross-validation schemes
For reference, we also ran all three cross validation schemes on the genetic data to
quantify and account for complex-related bias. The models confirm that, contrary
to the drugs-related input, the differences between the results for the different cross-
validation schemes were rather modest. For example, method raw with the STRING
network attains 0.59-0.64, 0.50-0.54 and 0.37-0.40 hits in the top 20 under the
classical, block and representative cross-validation strategies. The slightly larger
negative effect on top 20 hits observed with the representative scheme is expected
because the number of positives that act as validation decreased and this metric
is biased by the class imbalance. The agreement between method ranking using
AUPRC and top 20 hits was less consistent, possibly due to the performance drop,
whilst AUROC again yielded quite a different ranking. Further data can be found
in the supplement, tables S15 and S16.
Comparing networks
The change in performance for using the OmniPath network instead of the filtered
STRING network was also limited. For AUROC the effect was negative, whereas for
the top 20 hits metric the performance improved. Method raw changed from 0.50-
0.54 top 20 hits in STRING to 0.61-0.66 in OmniPath under the block validation
strategy.
Comparing methods
To be consistent with the drugs section, we take as reference the block cross-
validation strategy and the STRING network.
The baseline approach pr that effectively makes use of the network topology alone
proved difficult to improve upon, with 0.43-0.47 expected true hits in the top 20.
Methods raw and rf respectively achieved 0.50-0.54 and 0.23-0.26 – although sig-
nificant, the difference in practice would be minimal. The best performing method
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was mc with 0.65-0.7 hits. All the performance estimates can be found in the sup-
plement, table S16. To give an idea of the effort that would be required in a realistic
setting to find novel disease genes, the number of correct hits in the top 100 hits
was 3.29-3.45 with the best performing method (in this case, ppr), against 2.25-2.38
of pr.
Two main conclusions can be drawn from these results. First, the network topology
baseline retained some predictive power upon which most diffusion-based methods,
as well as machine-learning approaches COSNet and bagsvm, only managed to add
minor improvements, if any. Second, drug targets could still be found by combining
network analysis and genes with genetic associations to disease, but with a substan-
tially lower performance and with a marginal gain compared to a baseline approach
that would only use the network topology to find targets (e.g. by screening the most
connected genes in the network).
It is worth noting that gene-disease genetic association scores themselves have
drawbacks and that better prediction accuracy could result as genetic association
data improves.
Conclusions
We performed an extensive analysis of the ability of network-based approaches to
identify novel disease genes. We exhaustively explored the effect of different factors
including the biological network, the definition of disease genes, and the statistical
framework being used to evaluate methods performance. We show that carefully
choosing an appropriate cross-validation framework and suitable performance met-
ric have an important effect in evaluating the utility of these methods.
Our main conclusion is that network-based drug target discovery seems effective,
reflecting the fact that drug targets tend to cluster within the network. This in
turn may of course be due to the fact that the scientific community has so far
been focusing on testing the same proven mechanisms. In a strict cross-validation
setting, we found that even the most basic guilt-by-association method was useful,
with ∼2 correct hits in its top 20 predictions, compared to ∼0.1 when using a
random ranking. The best diffusion based algorithm improved that figure to ∼3.75,
and the best overall performing method was a random forest classifier on network-
based features (∼4.4 hits). Leading approaches can be notably different in terms
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of their top predictions, suggesting potential complementarity. We found a better
performance when using a network with more coverage at the expense of more false
positive interactions. In a more conservative network, random forest performance
dropped to ∼3.1 hits. Comparing performance on different diseases shows that the
more known target genes, and the more clustered these are in the network, the
better the performance of network-based approaches for finding novel targets for it.
We also explored the prediction of known drug target genes by seeding the network
with an indirect data stream, in particular, genetic association data. Here, the best
performing methods were diffusion-based and presented a statistically significant,
but marginal, improvement over approaches that only look at network connectivity.
We conclude that network propagation methods can help identify novel disease
genes, but that the choice of the input network and the seed scores on the genes
needs careful consideration. Based on our approach and endorsed benchmarks, we
recommend the use of methods employing representations of diffusion-based in-
formation (the MashUp network-based features and the diffusion kernels), namely
random forest, the support vector machine variants, and raw diffusion algorithms
for optimal results.
Methods
Selection of methods for investigation
Algorithms were selected for validation based on the following criteria:
1 published in a peer-reviewed journal, with evidence of improved performance
in gene disease prediction relative to contenders,
2 implemented as a well documented open source package, that is efficient, ro-
bust and usable within a batch testing framework,
3 directly applicable for gene disease identification from a single gene/protein
interaction network, without requiring fundamental changes to the approach
or additional annotation information and
4 capable of outputting a ranked list of individual genes (as opposed to gene
modules for example).
In addition, we selected methods that were representative of a diverse panel of
algorithms, including diffusion-based approaches, supervised learning approaches,
and a number of baseline approaches (see table 1).
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Testing framework, algorithms and parameterisation
All tests and batch runs were set-up and conducted using the R statistical pro-
gramming language [22]. When no R package was available, the methodology was
re-implemented, building upon existing R packages whenever possible. Standard
R machine learning libraries were used to train the support vector machine and
random forest classifiers. Only the MashUp algorithm [23] required feature gener-
ation outside of the R environment, using the Matlab code from their publication.
Further details on the methods implementation can be found in the supplement,
section “Method details”.
EGAD [24], a pure neighbour-voting approach, was used here as a baseline com-
parator.
Diffusion (propagation) methods are central in this study. We used the random
walk-based personalised PageRank [25], previously used in similar tasks [26], as
implemented in igraph [27]. The remaining diffusion-based methods were run on
top of the regularised Laplacian kernel [28], computed through diffuStats [29]. We
included the classical diffusion raw, a weighted approach version gm and two statis-
tically normalised scores (mc and z), as implemented in diffuStats. In the scope of
positive-unlabelled learning [30, 31], we included the kernelised scores knn and the
linear decayed wsld from RANKS [32]. Closing this category, we implemented the
bagging Support Vector Machine approach from ProDiGe1 [33], here bagsvm.
Purer ML-based methods were also included. On one hand, network-based features
were generated using MashUp [23] and two classical classifiers were fitted to them,
based on caret [34] and mlr [35]. These are svm, the Support Vector Machine as
implemented in kernlab [36], and rf, the Random Forest found in the randomForest
package [37]. On the other hand, we tried the parametric Hopfield recurrent neural
network classifier in the COSNet R package [38, 39].
Finally, we defined three naive baseline methods: (1) pr, a classic problem-na¨ıve
‘non-personalised’ PageRank implementation where input scores on the genes are
ignored; (2) randomraw, which applies the raw diffusion approach to randomly per-
muted input scores on the genes; and (3) random, a uniform re-ranking of input
genes without any network propagation. The inclusion of pr and randomraw al-
lowed us to quantify the predictive power of the network topology alone, without
any consideration for the input scores on the genes.
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Biological networks
The biological network used in the validation is of critical importance as current
network resources contain both false positive and false negative interactions, and
these will affect any subsequent predictions [20].
Here, we used two human networks with different general properties, one more
likely to contain false positive interactions (STRING [40]), and another more con-
servative (OmniPath [41]), to test the effect of the network itself on network prop-
agation performance. We further filtered STRING [40] to retain only a subset of
interactions. Having tested several filters, we settled upon high-confidence inter-
actions (combined score > 700) with some evidence from the “Experiments” or
“Databases” data sources (see supplement, table S2). Applying these filters and
taking the largest connected component resulted in a connected network of 11,748
nodes and 236,963 edges. Edges were assigned weights between 0 and 1 by rescaling
the STRING combined score.
We did not filter the OmniPath network [41]. After removing duplicated edges
and taking the largest connected component, the OmniPath network contained
8,580 nodes and 42,145 unweighted edges.
Disease gene data
We used the Open Targets platform [19] to select known disease-related genes. In
this analysis we define disease-related genes are those reported in Open Targets as
being the target of a known drug against the disease of interest, or as those with
a genetic association of sufficient confidence with the disease. Associations were bi-
narised: any non-zero drugs-related association was considered positive, implying
that the methods would predict genes on which a drug has been essayed, regardless
of whether the drug was eventually approved. Likewise, only genetic associations
with an Open Targets score above 0.16 (see supplement, figure S1) were consid-
ered positive. We considered exclusively common diseases with at least 1,000 Open
Targets associations, of which a minimum of 50 could be based on known released
drugs and 50 on genetic associations, in order to avoid empty folds in the nested
cross-validations. By applying these filters, we generated a list of phenotypes and
diseases which we then manually curated to remove cancers (where causal genetic
mechanisms can differ from those of other common diseases), non-disease pheno-
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type terms (e.g. “body weight and measures”) as well as vague or broad terms
(e.g.“cerebrovascular disorder” or “head disease”) and infectious diseases. This left
22 diseases considered in this study (table 2). Further descriptive material on the
role of disease genes within the STRING network can be found in the section “De-
scriptive disease statistics in the STRING network” from the supplement.
Validation strategies
Input Gene Scores
We used the binarised drug association scores and genetic association scores from
Open Targets as input gene-level scores to seed the network propagation analyses
(figure 8) and test their ability to recover known drug targets. With the first ap-
proach (subfigure (1) in figure 8), we tested the predictive power of current network
propagation methods for drug target identification using a direct source of evidence
(known drug targets). In the second approach (subfigure (2) in figure 8), we assessed
the ability of a reasonable but indirect source of evidence – genetic associations to
disease – in combination with network propagation to recover known drug targets.
Metrics
Methods were systematically compared using standard performance metrics. The
Area under the Receiver Operating Characteristic curve (AUROC) is extensively
used in the literature for binary classification of disease genes [42], but can be
misleading in this context given the extent of the class imbalance between target and
non-target genes [43]. We however included it in our benchmark for comparison with
previous literature. More suitable measures of success in this case are Area under
the Precision-Recall curve (AUPRC) [43] and partial AUROC (pAUROC) [44].
AUROC, AUPRC and pAUROC were computed with the precrec R package [45].
We also included top 20 hits, defined as the number of true positives in the top
20 predicted genes (proportional to precision at 20). It is straightforward, intuitive
and most likely to be useful in practice, such as a screening experiment where only
a small number of predicted hits can be assayed.
We considered another 3 metrics, reported only in Supplement, i.e. partial AU-
ROC up to 5% FPR, partial AUROC up to 10% FPR, and number of hits within
the top 100 genes.
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Cross validation schemes and protein complexes
Standard (stratified) and modified k-fold cross-validation were used to estimate
the performance of network-based methods. Folds were based upon known drugs-
related genes, regardless of which type of input was used (see figure 8). Genes in
the training fold were negatively or positively labelled according to the input type,
whereas genes in the validation fold were left unlabelled.
A fundamental challenge we faced when applying cross-validation to this prob-
lem was that known drug targets often consist in protein complexes, e.g. multi-
protein receptors. Drug-target associations typically have complex-level resolution.
The drug target data from Open Targets comes from ChEmbl [46], in which all the
proteins in the targeted complex are labelled as targets.
If left uncorrected, this could bias our cross-validation results: networks densely
connect proteins within a complex, random folds would frequently split positively
labelled complexes between train and validation, and therefore network-based meth-
ods would have an unfair advantage at spotting positive hits in the training folds.
In view of this, we benchmarked the methods under three cross validation strate-
gies: a standard cross validation (A) in line with usual practice and two (B, C)
complex-aware schemes (figure 9) addressing non-independence between folds when
the known drug targets act as input.
Strategy (A), called classic, was a regular stratified k-fold repeated cross-
validation. We used k = 3 folds, averaging metrics over each set of folds, repeated
25 times (see also figure 1).
Strategy (B), named block, performed a repeated cross validation while explicitly
preventing any complexes that contain disease genes to be split across folds. The key
point is that, where involved, shuﬄing was performed at the complex level instead
of the gene level – overlapping complexes that shared at least one known drug target
were merged into a larger pseudo-complex before shuﬄing. Fold boundaries were
chosen so that no complex was divided into two folds, while keeping them as close
as possible to those that would give a balanced partition, see figure 9. Nevertheless,
a limitation of this scheme is that it can fail to balance fold sizes in the presence
of large complexes (see supplement, figure S9). For example, chronic obstructive
pulmonary disease exhibited imbalanced folds, as 50 of the proteins involved belong
to the Mitochondrial Complex I
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/439620doi: bioRxiv preprint first posted online Oct. 11, 2018; 
Picart-Armada et al. Page 15 of 28
1 1
2 2
3 3
4 4
5 5
6 6
7 7
8 8
9 9
10 10
11 11
12 12
13 13
14 14
15 15
16 16
17 17
18 18
19 19
20 20
21 21
22 22
23 23
24 24
25 25
26 26
27 27
28 28
29 29
30 30
31 31
32 32
33 33
Strategy (C), referred to as representative, selected only a single representative
or prototype gene for each complex to ensure that gene information in a complex
was not mixed between training and validation folds. In each repetition of cross val-
idation, after merging the overlapping complexes, a single gene from each complex
was chosen uniformly at random and kept as positive. The remaining genes from the
complexes involved in the disease were set aside from the training and validation
sets, in order (1) not to mislead methods into assuming their labels were negative
in the training phase, and (2) not to overestimate (if set as positives) or penalise
(if set as negatives) methods that ranked them highly, as they were expected to do
so. This strategy kept the folds balanced, but at the expense of a possible loss of
information by summarising each complex by a single gene at a time, reducing the
number of positives for training and validation.
Additive performance models
For a systematic comparison between diseases, methods, cross-validation schemes
and input types, we fitted an additive regression model to the performance metrics of
each (averaged) fold from the cross-validation. The use of main effect models eased
the evaluation of each individual factor while correcting for the other covariates.
We modelled each metric f separately for each input type, not to mix problems of
different nature:
f ∼ cv scheme + network + method + disease
We fitted dispersion-adjusted logistic-like quasibinomial distributions for the met-
rics AUROC, pAUROC and AUPRC and quasipoisson for top k hits. The effect of
changing any of the four main effects is discussed in separate sub-sections in Re-
sults, following the order from the formula above. After a data driven choice of
cross-validation scheme and network we fitted reduced models within them for a
more accurate description:
f ∼ method + disease
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Qualitative methods comparison
The rankings produced by the different algorithms were qualitatively compared us-
ing Spearman’s footrule [47]. Distances were computed between all method ranking
pairs for each individual combination of disease, input type, network and for the
top N predicted genes, excluding the original seed genes. This part does not involve
cross validation – all known disease-associated genes were used for gene prioriti-
sations. Pairs of rankings could include genes uniquely ranked highly by a single
algorithm from the comparison, so mismatch counts (i.e. percentage mismatches)
between these rankings were also taken into account. Mismatches occur when a
gene features in the top N predictions of one algorithm and is missing from the
corresponding ranking by another algorithm. A compact visualisation of distance
matrices was obtained using a multi-view extension of MDS [48, 49, 50]. For this
we used the R package multiview [51] that generates a single, low-dimensional pro-
jection of combined inputs (disease, input and network).
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Figures
Tables
Table 1 List of methods included in this benchmark. Method identifiers are shortened method
names used throughout the text. Other columns are self-explanatory.
Method Identifier Method Name Method Class Implementation Reference
pr PageRank with a uniform prior Baseline igraph (Bioconductor [52, 53] package) [25]
random Random Baseline R (see text)
randomraw Random Raw Baseline R (see text)
EGAD Extending Guilt by Association’ by Degree Baseline EGAD (Bioconductor package) [24]
ppr Personalized PageRank Diffusion igraph (R package) [26]
raw Raw Diffusion Diffusion diffuStats (Bioconductor package) [54]
gm GeneMania-based weights Diffusion diffuStats (Bioconductor package) [55]
mc Monte Carlo normalised scores Diffusion diffuStats (Bioconductor package) [56]
z Z-scores Diffusion diffuStats (Bioconductor package) [57]
knn K nearest neighbours Semi-supervised learning RANKS (R package) [58]
wsld Weighted Sum with Linear Decay Semi-supervised learning RANKS (R package) [58]
COSNet COst Sensitive neural Network Supervised learning COSNet (R package) [38]
bagsvm Bagging SVM (based on ProDiGe1) Supervised learning kernlab (R package) [33]
rf Random Forest Supervised learning randomForest (R package) + Matlab (features) [23]
svm Support Vector Machine Supervised learning kernlab (R package) + Matlab (features) [23]
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Table 2 List of diseases included in this study. Diseases included in this study, with a minimum of
50 associated genes both in the known drug targets and the genetic categories (see text). The overlap
between these two lists of genes showed a degree of dependence between these two Open Targets
data streams for some of the diseases. P-values were calculated using Fisher’s exact test and are
reported without and with correction for false discovery rate (Benjamini and Hochberg [59]).
Disease N(genetic) N(drugs) Overlap P-value FDR
allergy 112 57 1 4.22e-01 4.42e-01
Alzheimers disease 208 103 4 1.10e-01 1.42e-01
arthritis 174 188 6 6.08e-02 1.03e-01
asthma 105 80 6 7.77e-05 5.70e-04
bipolar disorder 117 148 3 1.83e-01 2.12e-01
cardiac arrhythmia 75 177 6 9.15e-04 3.36e-03
chronic obstructive pulmonary disease (COPD) 154 116 6 4.18e-03 1.31e-02
coronary heart disease 111 171 4 7.86e-02 1.24e-01
drug dependence 75 143 6 2.96e-04 1.30e-03
hypertension 66 188 2 2.85e-01 3.14e-01
multiple sclerosis 71 167 4 1.83e-02 4.03e-02
obesity 69 194 3 1.06e-01 1.42e-01
Parkinson’s disease 55 145 0 1 1
psoriasis 131 105 7 1.68e-04 9.23e-04
rheumatoid arthritis 138 95 5 5.18e-03 1.42e-02
schizophrenia 410 163 17 5.44e-05 5.70e-04
stroke 90 156 3 1.18e-01 1.44e-01
systemic lupus erythematosus (lupus) 126 109 5 6.30e-03 1.54e-02
type I diabetes mellitus 87 106 3 4.39e-02 8.04e-02
type II diabetes mellitus 130 154 4 9.14e-02 1.34e-01
ulcerative colitis 136 51 7 1.81e-06 3.98e-05
unipolar depression 123 121 4 3.81e-02 7.63e-02
Additional Files
Additional file 1 — Supplement
This document contains complementary material that supports our claims in the main body. It includes topics such
as descriptive statistics, topological properties of disease genes, raw metrics plots, method details, MDS plots,
alternative performance metrics and further explicative models.
Additional file 2 — MDS plots
Complementary single-disease MDS plots and distance matrices.
Additional file 3 — Interactions html viewer
Stand-alone viewer to explore models with interaction terms.
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Figure 1 Benchmark overview. This work describes six performance metrics using two input
streams (genetic association and drug-based genes) to predict drug-based genes for 22 common
diseases. 3-fold cross validation (CV), repeated 25 times, was run under three CV strategies. The
gene identifiers in each fold are determined using only the drugs data, regardless of the input.
Two validation strategies are complex-aware and therefore needed this data to define the splits. 15
network-based methods (including 4 baselines) were evaluated, using two networks with different
properties, by modelling their performance, averaged on every CV round. The explanatory models
allowed hypothesis testing and a direct comparison between diseases, CV strategies, networks and
methods.
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Figure 2 Additive models for AUROC and top 20 hits. Each column corresponds to a different
model, whereas each row depicts the 95% confidence interval for each model coefficient. Rows are
grouped by the categorical variable they belong to: method, cv scheme, network and disease. Each
variable has a reference level, implicit in the intercept and specified in brackets: pr method,
classic validation scheme, STRING network and allergy. Positive estimates improve performance
over the reference levels, whereas negative ones reduce it. For example, the data suggest that
method rf performs better than the baseline using both metrics, and is the preferred method
using the top 20 hits. Switching from STRING to the OmniPath network, or from classic to block
or representative cross-validation, has a negative effect on both performance metrics. Specific
model estimates and confidence intervals can be found in the supplement, see tables S8 and S9.
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/439620doi: bioRxiv preprint first posted online Oct. 11, 2018; 
Picart-Armada et al. Page 23 of 28
1 1
2 2
3 3
4 4
5 5
6 6
7 7
8 8
9 9
10 10
11 11
12 12
13 13
14 14
15 15
16 16
17 17
18 18
19 19
20 20
21 21
22 22
23 23
24 24
25 25
26 26
27 27
28 28
29 29
30 30
31 31
32 32
33 33
Figure 3 Performance predicted for AUROC and top 20 hits through the additive models. Each
row corresponds to a different model and error bars depicts the 95% confidence interval of the
additive model prediction, averaging over diseases. In bold, the main network (STRING) and
metrics (AUPRC, top 20 hits). A table with the exact values can be found in the supplement,
table S9.
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Figure 4 Multi-view MDS plot displaying the preserved Spearman’s footrule distances between
methods. The differential ranking of their top 100 novel predictions using known drug target
inputs are taken into account across all 22 diseases. Results are shown separately for the 2
networks considered in this study. Seed genes are excluded from the distance calculations.
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Figure 5 Pairwise contrasts on top 20 hits predicted by the quasipoisson model. Differences are
expressed in the model space. Most of the pairwise differences are significant (Tukey’s test, p
<0.05) – non-significant differences have been crossed out.
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Figure 6 Ranking of all the methods, using the predictions of the main and the reduced models
on the drugs input, STRING network, block cross validation and averaging over diseases. A
column-wise z-score on the predicted mean is depicted, in order to illustrate the magnitude of the
difference.
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Figure 7 Disease performance ranked by the number of known disease genes from known drug
data and modularity of known disease genes (obtained using the igraph package, see supplement,
figure S6). Modularity is a measure of the tendency of known disease genes to form modules or
clusters in the network. Diseases have been ranked using their coefficient from the top 20 hits
metric with known drug targets as input (x axis) and their modularity (y axis). As discussed in the
text, best predicted diseases tend to have longer gene lists and be highly modular.
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Figure 8 Input Gene Scores. Two input types were used to feed the prioritisation algorithms:
the binary drug scores and the binary genetic scores. CV folds were always calculated taking into
account the drugs input and reused on the genetic input.
Figure 9 Cross-validation schemes. Three cross-validation schemes were tested. (A):
standard k-fold stratified cross-validation that ignored the complex structure. (B): block k-fold
cross-validation. Overlapping complexes were merged and the resulting complexes were shuﬄed.
The folds were computed as evenly as possible without breaking any complex. (C): representative
k-fold cross validation. Overlapping complexes were merged and the resulting complexes from
which unique representatives were chosen uniformly at random. Then a standard k-fold
cross-validation was run on the representatives, but excluding the non-representatives from train
and validation.
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